Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.49 |
| ▸ | MME | P08473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9485864 | 0.93 | CTSC (0.57) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL4434435 | 0.93 | CTSC (0.57) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL4434431 | 0.93 | CTSC (0.57) | CTSCALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL30698079 | 0.92 | CTSC (0.56) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL30051660 | 0.91 | CTSD (0.55) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL30052830 | 0.88 | OPRD1 (0.53) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL29377179 | 0.87 | MME (0.57) | CTSCALPIPKMPTGS1XIAP | |
| SCHEMBL30052163 | 0.87 | CTSD (0.54) | CTSCALPIPKMPTGS1XIAP | |
| Trifluoroacetic Acid SCHEMBL16050210 | 0.86 | LTA4H (0.57) | CTSCALPIPKMPTGS1XIAP | |
| Trifluoroacetic Acid SCHEMBL1163885 | 0.86 | CTSC (0.56) | CTSCALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG (CN) | 2012-12-06 | — | — | US | disclosed |
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ZHANG HESHENG | 2009-12-31 | — | — | US | disclosed |
| EP-2123283-A1 | THE TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER EFFECT | Tianjin Hemey Bio-Tech Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325894-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | GLS2, GLS, VIP | CTSC 2966/4885ALPI 73/4885PKM 2571/4885 |
| US-20120308646-A1 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES | ALAD, SLC27A2, ANTXR2 | CTSC 1123/4885ALPI 560/4885PKM 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.